Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor

BASEL, SWITZERLAND / ACCESSWIRE / June 14, 2024 / Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, proudly announces the appointment of Virginia Savova, PhD as a strategic and scientific advisor.

Dr. Savova brings strong expertise in computational biology, immunology, and cancer research, with a track record of high-profile publications. She has pioneered the development and application of single-cell technologies and the use of AI in single-cell data analysis at prestigious institutions such as Harvard Medical School and Dana Farber Cancer Institute.

As Senior Director of the Single-cell Biology group at Sanofi, she advanced single-cell technologies for systematic, data-driven target and biomarker discovery across multiple immune indications, supporting various stages in drug development. "Scailyte is an exciting new player in single-cell precision medicine and I am thrilled to support the team in their journey," said Virginia Savova.

Peter Nestorov, Co-Founder and CEO of Scailyte, commented: "Virginia combines a passion for innovation and cutting-edge technologies with a vision for biomarker-driven drug discovery. Her engagement will advance Scailyte towards becoming a global biomarker discovery leader."

With Virginia's appointment, Scailyte has further strengthened its expertise with an experienced industry leader who will play an important role in shaping the company's future. The company remains committed to advancing the field of precision medicine with single-cell technologies, artificial intelligence, and multi-omics analysis.